drugset / Trial / NCT05240456
Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children
RandomizedParallel-groupTriple-blindTreatment
Summary
A randomized clinical study to evaluate the safety and efficacy of using the Beta 3 agonist drug (Mirabegron) combined with standard behavioral therapy in comparison to using the anticholinergic drug (Solifenacin) combined with behavioral therapy, for children with non-neurogenic voiding dysfunction refractory to behavioral therapy alone, using improvement of dysfunctional voiding symptom score as a primary measurement of efficacy.
Timeline
- Start
- 2022-02
- Primary completion
- 2022-07
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirabegron | Other / unclassified | 25 mg | — |
| Subject | Mirabegron | Other / unclassified | 50 mg | — |
| Comparator | Solifenacin | Small molecule | 2.5 mg/kg | — |
| Comparator | Solifenacin | Small molecule | 10 mg/kg | — |